AI-generated · cited to primary sources · not investment advice
Fortis Health. (532843) Aug 2025 Filing Analysis
Does management do what it says?
The Manesar facility achieved EBITDA positive status in less than one year, ahead of previous expectations. (1 exceeded, 3 met across 4 tracked commitments)
“I am expecting if we're able to achieve the revenue of INR2 crores more per month, which we are expecting in the next couple of months, this unit should be breakeven on EBITDA level.”
Hospital business ARPOB for Q2 FY26 was INR 2.51 Cr, representing a 5.8% growth YoY, which is exactly within the guided range. (1 met across 1 tracked commitment)
“but we maintain our guidance that ARPOB growth should be in the -- in the normal course, it should be around 5%, 6%.”
The company plans to add 4 new robotic machines across the network within the current year at a capex of approximately INR 12 crores per da Vinci unit. — target: 4 robotic machines
“So we have approximately 15 robotic machines across our network right now, and we are in the process of getting another 4 this year.”
See the full cited Management analysis of Fortis Health.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.